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Executive Summary
The use of ions to deliver radiation to a body for therapeutic purposes has the
potential to be a significant improvement over the use of low linear energy transfer (LET)
radiation because of the improved energy deposition profile and the enhanced biological
effects of ions relative to photons.  Proton therapy centers exist and are being used to treat
patients.  In addition, the initial use of heavy ions such as carbon is promising to the point
that new treatment facilities are planned.  Just as with protons or heavy ions, antiprotons can
be used to deliver radiation to the body in a controlled way; however antiprotons will exhibit
additional energy deposition due to annihilation of the antiprotons within the body.  The
slowing down of antiprotons in matter is similar to that of protons except at the very end of
the range beyond the Bragg peak.  Gray and Kalogeropoulos estimated the additional energy
deposited by heavy nuclear fragments within a few millimeters of the annihilation vertex to
be approximately 30 MeV (Gr84).  Kalogeropoulos and Muratore also mentioned the
advantage of using the fast pions leaving the body to image the annihilation event (Ka89).  In
1985, Sullivan measured the relative magnitude of this enhanced energy deposition at the
Low Energy Antiproton Ring (LEAR) at CERN, but he did not measure the biological effect
(Su85).  Our proposed experiment is the first to measure directly the biological effects of
antiproton annihilation.  The experiment can only be done at CERN at this time because only
the Antiproton Decelerator (AD) at CERN has a monoenergetic beam of antiprotons able to
deliver a biologically meaningful dose at an appropriate dose rate.
We propose to use a monochromatic beam of antiprotons at 300 MeV/c momentum
extracted from the AD into the DEM line to irradiate biological cell samples. Preliminary
discussions with members of the AD operations team indicate that no significant
modifications of the AD or the DEM beamline will be required.  The physical footprint of the
proposed experiment is approximately 2 m2 and will fit in the space currently available at the
end of the DEM beamline. After characterizing the beam profile, cell samples will be
exposed to various doses of antiprotons and their survival will be measured.  For the purpose
of cell preparation and biological analysis we plan to install a small biolab outside the AD
accelerator hall in an existing container presently owned by the ATHENA collaboration. All
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We will make no financial or manpower requests to CERN, except for the request to the AD
operations team for beam extraction into the DEM line at 300 MeV/c.
The total number of full 8-hour shifts requested is nine. The proposed test beam
experiment is designed to have minimal impact on the existing AD experiments and can
make use of gaps in the usage of the AD caused by experimental downtime. Once the
measurements described in this document are completed, there will be an evaluation phase
and a presentation of the results.  If these results promise significant enhancement over other
methods, we will consider a follow-up proposal.
I. Purpose
The purpose of the proposed experiment is to measure the biological effectiveness of
the annihilation of stopped antiprotons relative to protons and to determine the peripheral
damage profile associated with the possible therapeutic use of antiprotons for radiosurgery.
II. Background and Importance
Gray and Kalogeropoulos (Gr84) first proposed using antiprotons for treating tumors
in 1984.  They observed that the added energy deposited by the nuclear fragments generated
during the final annihilation could provide a significantly greater biological effect than
protons or heavy ions.  All ions share the specific profile of increased energy deposition at
the end of their range in materials, which has the potential to make them far superior to x-
rays and photons for radiation therapies.  The observations of Gray and Kalogeropoulos came
at a time when quality beams of antiprotons were just emerging and they correctly predicted
much future development in this area.  A year later Sullivan performed an experiment
measuring the actual energy deposition of antiprotons stopping in tissue-equivalent plastic
and found an enhancement over protons of at least 20 MeV/antiproton (Su85).  While this is
small compared to the total annihilation energy of 2 GeV, for biological purposes this is very
significant.  Most of the energy of the annihilation is carried away by the charged pions or
high-energy gammas (resulting from the immediate decay of neutral pions) with minimal
interactions with the surrounding tissue.  The higher energy neutrons emitted in the
annihilation process have intermediate ranges and result in a diffuse neutron radiation
background centered on the tumor, but extending beyond the targeted region.  Similarly, the
higher energy protons and pions can produce some background radiation beyond the
immediate region of annihilation.  The main biological efficacy of antiprotons stems from the
heavy recoils and fragments that result from a fraction of the many annihilation events where
one of the pions may interact with a proton or neutron in the nucleus to cause nuclear
excitation with subsequent break-up.  These heavy fragments and recoils have a very short
range and deposit all their energy in a localized region around the annihilation vertex.
Kalogeropoulos also noted that the high-energy pions can be used for 3-D imaging of the
annihilation point, which is an important enhancement compared to both proton and heavy
ion treatments.
No experimental measurement of the biological effect of antiprotons annihilating in
human-like tissue exists, and it is this important quantity that is the focus of our proposed
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(AD) we propose to measure directly the biological effect of antiprotons on living cells.
These cells will be uniformly distributed in agarose, a biological culture medium, for their
exposure to antiprotons.  We will examine the survival of cells in response to different
radiation doses generated by antiproton annihilations.  This is the first measurement of this
kind ever performed and will thus have an important impact on the field of particle beam-
based cancer therapy.  Even if the enhanced energy deposition is not as biologically
significant as expected by many researchers in this field, the resulting measurement is very
important and noteworthy.  Twenty years after Gray and Kalogeropoulos introduced the idea
of antiproton treatments as a future possibility, antiproton beams of the needed quality exist
at the CERN AD that can enable us to evaluate this potentially powerful treatment
methodology.
The response of biological systems to radiation is given in terms of dose, type of
radiation, and biological effect.  Dose (absorbed energy/mass) is measured in units of Gray
(Gy) where 1 Gy = 1 joule/kg in any material.  The energy and type of radiation are important
because the same dose delivered by photons, electrons, protons, neutrons, alpha particles,
carbon ions, etc. at different incident energies and dose rates can have significantly different
biological effects.  Comparisons between the biological effects of different types of radiation
are usually expressed in terms of Relative Biological Effectiveness (RBE).  RBE is the ratio
of the dose of photon radiation to the dose of a reference radiation that produces the same
biological effect. However, the RBE can also be measured for biological response in the
Bragg peak region compared with that in the incident plateau region of an ion energy loss
distribution.  We propose to measure an RBE for antiprotons by comparing the biological
effect of specific doses of antiprotons at a fixed energy relative to proton beams of similar
energy and 60Co radiation. 60Co has replaced 250 kVp (250 kV peak) x-rays as the reference
radiation and has been used historically in biological characterization of this nature.  In this
manner, the measurements of antiproton RBE will enable us to compare antiprotons to
all the previous work that has been done in the field of charged particle delivery of
radiation.
Antiproton annihilation in biological material and the complexity of biological
response do not lend themselves to calculations from first principles.  In fact, there is
considerable misunderstanding of the source of the enhanced biological effects of
annihilation.  The majority of the annihilation products such as pions, gammas, or other low
LET radiation contribute to a diffuse non-localized background dose to the whole body.
From a potential therapeutic perspective the short-range, low-energy recoils and fragments
are the most significant because they deposit high LET radiation that is known to have
enhanced biological effect.  Comparing biological effectiveness of antiproton annihilation in
the peak versus plateau regions of the stopping ionization distribution will give us some idea
of the potential differentials in "biological" dose in the tumor and surrounding normal tissues
for a therapeutic beam of antiprotons.  The peripheral biological damage associated with
annihilation is a second measurement to be made in this experiment.  The non-localized
mixed radiation fields (neutrons, pions, muons, gammas) due to annihilation will also
produce biological effects that must be measured as a function of distance from the point of
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antiproton delivery and the relative biological effectiveness of ionizations in the peak versus
those in the plateau will determine the potential efficacy of antiproton radiation therapy.
III. Scientific Approach
We propose to perform a biological test beam experiment using approximately 300
MeV/c (50 MeV) antiprotons from the AD extracted into a biological phantom situated in air
at the end of the DEM beamline as shown in Figure 1.  The choice of momentum is
motivated by the range and straggling of antiprotons at this momentum.  The phantom
surrounds a biological sample of live cells and is essentially a volume of tissue-equivalent
material that simulates the effect of backscattering and energy absorption in a human body.
The biological sample is contained within a tube, which is designed to hold dispersions of the
live cells in agarose, a semi-solid biological culture medium..  The quantitative cell survival
studies involve counting the number of colonies that grow during an incubation period after
irradiation, compared with controls receiving zero doses.  A standard cell line of known
radiation sensitivity will be exposed to varying doses of antiprotons.  The beam pulses and
repetition rate of the AD can provide radiation dose rates in the cell-containing volume of
interest of approximately 9 Gy/hr for a 1-cm2 spot size.  The total doses of biological interest
are expected to be in the range of 0.1 - 10 Gy, although lower doses may be sufficient if the
RBE is high.  The analysis of cell survival at serial 1 mm depths along the beam central axis
will enable us to determine the RBE as a function of depth along the path of antiprotons.  The
RBE will reflect the net effect of all different ionization species along the antiproton path and
will be measured by comparing the survival of cells versus depth.  The response relative to
both protons and 60Co will also be determined to standardize the biological effectiveness of
antiprotons.  The peripheral biological effects of the non-localized mixed radiation fields
away from the point of annihilation will be measured in cell samples located at appropriate
distances from the region of annihilation.
This biological test beam experiment is designed to have minimal impact on the
existing AD experiments.  The required number of antiprotons for a complete set of
biological samples can be delivered in nine shifts of AD operation including necessary beam
characterization and physical dose measurements (See Table III & IV).  The experiment to
measure the relative biological effect of the annihilation of stopped antiprotons is highly
interdisciplinary.  The collaborators for this experiment cover the scientific disciplines
needed.  The collaborative relationship includes personnel from PBar Medical, Inc., UCLA
Medical School, University of Aarhus, and CERN.
IV. Experimental Design
Even with the limited amount of beam time requested, the proposed measurements
will give crucial information about the potential of therapeutic treatments using antiprotons.
Table I lists the experimental parameters relevant to the design of this biological test beam
experiment.
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Typical linear cell dimension 10-3 cm
Cell number density (tumor) 109 per cm3
Tissue density 1 g/cm3
Cell number density (suspension) 7x105 / cm3
Culture medium density (agarose) 1 g/cm3
Range (300 MeV/c antiproton) in water 2.2 cm
Longitudinal straggling 1.5 mm
Antiproton source from AD 2x107/200 nsec pulse every 2 minutes
5 Gy dose ~109 annihilations/g
The usual method of measuring RBE involves comparing the dose of specific radiation to
produce a given biological effect with the dose of 60Co required to produce the same
biological effect.  The dose is delivered uniformly over relatively large volumes (several
cubic centimeters).  In the case of 60Co this is straightforward, but for the radiation produced
by the annihilation of antiprotons this is very difficult.  The radiation from annihilation is
mixed (pions, gammas, neutrons, fragments, recoils) and it is not easily possible to expose a
several cubic centimeter volume to a uniform dose of "annihilation radiation."  In the case of
protons and antiprotons, the localized dose is strongly dependent on depth as the particles
slow down and has a steep maximum at the end of the range.
The sliced gel technique of Skarsgard will be adopted for these studies (Sk82, Sk98).
In brief, cells will be suspended in solidified agarose growth medium within a tube.  The
tubes will be placed in a phantom, positioned collinear to the axis of the beam, and irradiated
to a certain total dose with the antiproton beam.  After the exposure is complete the gel will
be extruded from the tube using a plunger connected to a delivery mechanism that advances
the gel by 1 mm each time. The gel will be sliced every 1 mm using a taut wire, collected,
and weighed to determine the amount of gel, and therefore the number of randomly
distributed cells in each serial section.  Each slice will be dissolved in warm medium and
cells plated in Petri dishes at numbers likely to give 100 colonies per dish (which requires
different starting cell densities in the medium).  After incubation for 8-10 days in a controlled
environment, the colonies that develop will be stained and counted.  Only those colonies
having more than 50 cells will be counted as having been derived from a single surviving cell
(smaller colonies represent cells that successfully negotiated a series of doublings before their
reproductive death).  Survival curves will be fitted using the usual non-linear curve fitting
routines and effective equivalent RBE values will be calculated (Wo96) as a function of
depth in the sample.  The changes in the surviving fraction of cells with depth are due to the
combined effects of the change in local dose (Bragg peak + fragments) and the RBE.  Lateral
uniformity of the beam will be determined at a few selected depths by also measuring cell
survival versus radial position within selected slices.  The same procedure will be followed
6for determining survival curves for proton irradiation. The 60Co gamma biological control
reference irradiations are technically easier and will be performed using the same medium but
standard in-vitro cell culture conditions.
V. Experimental Set-up
Figure 2 is a schematic diagram of the proposed test experiment at CERN.  We
request permission to use the DEM beam line at an extraction momentum of approximately
50 MeV (300 MeV/c.).  Initial discussions with members of the AD operations team indicate
that extraction at this energy is feasible with existing instrumentation of the AD ring with a
few modifications and upgrades as indicated below. The beam line is fully operational and
has been used for tests at 100 MeV/c. To increase the momentum to 300 MeV/c may require
an upgrade of some of the power supplies, and all costs related to this upgrade will be
covered by our collaboration. The extraction will be performed on the standard 300 MeV/c
plateau after the normal electron cooling of the beam. It has been indicated to us that the
capture on h=1 instead of the normal h=3 harmonic can be accomplished with the existing
low-level hardware, allowing some time for recabling, set-up and testing. Some changes to
the software program and a possible change of the power supply for the extraction septum
should allow the switching between 300 MeV/c and 100 MeV/c extractions to be as simple
and fast as the present switching between the three main experiments.
The preferred beam profile for our experiment is one that is constant in spot size over
the length of the active experiment of 10 cm and has intensity variations of less than 20%
over the central 1 cm diameter. For a Gaussian profile this requires a FWHM of the beam of
3 cm. The DEM beam line with a schematic layout of the experiment is shown in figure 3.
With the 5 quadrupoles indicated in this drawing we expect to have enough control over the
beam to achieve this requirement. While this is contingent on the results of further and more
detailed calculations, we would like to point out that we can also accommodate different
beam profiles by altering the experimental procedure followed. For example, a smaller beam
diameter can be accommodated through lateral scanning of the beam across the target.
Because the experimental set-up will be in air, the beam will exit the AD vacuum system
through a thin window.  This window shall be optimized to minimize energy straggling and
radial scattering and can be either a standard beryllium window from the CERN group or a
specially fabricated window like the titanium window used at the entrance of the ATHENA
experiment. This window will be designed and certified in close collaboration with the
CERN AD staff.  Monitoring of the beam intensity and profile will be accomplished using a
parallel plate secondary emission chamber.  These systems have been used in varying designs
by several experiments at LEAR and the AD, including Crystal Barrel, PS200, TRAP, and
ASACUSA.  Due to the well-defined electric fields present in these designs, many of the
non-linear features of wire chambers can be avoided.  Linear response to the antiproton
intensity has been obtained by both PS200 and ASACUSA over a range of antiproton
intensities from 105 to 108 antiprotons/200 ns. The basic design consists of three thin foils,
coated with electrically conducting surfaces, a common anode plane and two cathode planes.
The cathode planes contain horizontal and vertical strips that allow a full measurement of the
2-D beam profile.  We intend to use an ultra-high vacuum-compatible system designed and
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beam line vacuum at the very exit of this line. This monitor has a 99% transmission for the
antiproton beam and, due to the insignificant amount of material it presents to the beam, has
only minimal impact on the energy and spatial straggling of the beam pulse. Therefore, this
detector can remain in the beam during the entire experiment. In addition, the AD team has
informed us that a silicon strip detector was installed last year at the focal point of the DEM
line. This detector can be left in place and used as a secondary detector to establish beam
profile, direction, and emittance. As a secondary beam monitoring system, we plan to use
scintillators coupled to hybrid photo diodes (HPD’s) (Fu02) as in the ATHENA experiment.
Alternatively, we may also explore using fine mesh Cherenkov detectors, which have been
shown to be less prone to saturation effects. These detectors will surround the biological
experimental set-up and monitor the high-energy pions and gammas resulting from antiproton
annihilations in the set-up. The large dynamic range of these systems again assures a linear
response to the intensity of the AD pulse delivered to the experiment. Both the secondary
emission chamber and the HPD-scintillator combinations will be calibrated against an
aluminum activation measurement as used by the ATHENA and ASACUSA collaborations
and described in detail in reference (Fu00).
Biological response is a function of the absolute dose delivered.  Thus the
determination of absolute absorbed dose is one of the most important measurements required
for this project. Additionally, absorbed dose to water (which closely resembles human tissue)
is the quantity that is used to specify the amount of radiation to be used in clinical practice.
Calorimetry is considered the gold standard for the determination of absolute dose, although
it is impractical and difficult to perform with a high degree of precision in short beam time
periods.  Calorimetry is further hindered by the small field size of the antiproton beam
available for this project. For practical reasons then, (calibrated) ionization chambers are
most commonly used.  For megavoltage electron and photon beams, the absolute dose in a
medium, Dmed (z), is typically determined using a dosimetry protocol (AA83, IA87, IC84).
These dosimetry protocols are based on the Spencer–Attix cavity theory (Sp55).  Several
investigators have extended this formalism to proton beams (AA86, Me95, Va96a, Va96b,
Vy91, Vy94). The extension to dosimetry of pion beams has also been described (Di76).
However, two characteristics prevent successful implementation for antiproton dosimetry.
First, the secondary radiation produced in an annihilation event is highly energetic and
reasonably isotropic in nature.  Therefore, the requirement of charged particle equilibrium in
the Spencer–Attix theory is violated.  Second, the high instantaneous dose rate of the CERN
AD beam precludes the use of ionization chambers.  Therefore, in lieu of a direct
determination of absolute dose, we propose two alternate methods. First, absolute dose can be
calculated using Monte Carlo codes if an appropriate means of measuring integrated beam
current is available.  Second, we propose a systematic evaluation of beam characteristics
using a variety of detectors with antiproton response correlated to appropriate reference
beams including 60Co and protons of a similar quality.  With absolute dosimetry obtained for
the reference beams, the antiproton response can be correlated with absolute dose and a
meaningful determination of the RBE obtained.
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The number of antiprotons and the required beam time to deliver a prescribed dose is
based upon calculations using an extension of the general-purpose Monte Carlo N-Particle
(MCNP) code, MCNPX, the Monte Carlo N-Particle Transport Code System for
Multiparticle and High Energy Applications.  MCNPX is an extension of earlier MCNP
codes with the addition of multiple particle transport and the incorporation of high-energy
particle physics models to compute interaction probabilities where table-based data are not
available.  The code combines the traditional MCNP particles (neutrons, photons, and
electrons) with the high-energy, multi-particle transport features of the Los Alamos High
Energy Transport (LAHET™) code system (LCS™).  The Intra-Nuclear Cascade (INC)
model currently used in MCNPX for simulating antiproton annihilation is based upon the
ISABEL (Ya79, Ya81) and VEGAS (Ch68) nuclear interaction codes including the emission
of charged and neutral pions and kaons.  The de-excitation of the residual nucleus after the
initial annihilation reaction is modeled using a multistage, multi-step pre-equilibrium exciton
model or MPM (Pr88) and includes the emission of protons, neutrons, deuterons, tritons, 3He
ions, and 4He ions.  Upon reaching an equilibrium condition the Fermi-Breakup model (Br81)
is applied to the residual nucleus and simulates the multi-fragmentation of light nuclei based
upon two- or three-body breakup channels.  Based upon an incident antiproton energy of
approximately 50 MeV, pulse rate of 2x107 antiprotons per 200 nsec AD beam pulse every
two minutes, and a uniform 1 cm x 1 cm spot size we estimate a dose rate of approximately
45 cGy per AD beam pulse or 13.5 Gy per hour in the region of annihilation.  The
assumption of a uniform spot size represents a best-case scenario with respect to required
beam time and lateral dose uniformity at the annihilation point.  The MCNPX calculations
will also be compared to Geant4 calculations and benchmarked against existing experimental
data.
Measurement Overview
Characterization of relative dose requires a detector linearity of response within the
assumed range of measurement conditions.  In addition to response linearity of a detector
used for relative measurement, appropriate sensitivity, energy independence, and spatial
resolution are desired.  We propose to investigate several detectors and methodologies for the
purpose of evaluating and verifying the depth-dose characteristics of an antiproton beam.
These include the following: thermoluminescent dosimeter (TLD), film, and BANG
dosimeter. The specific measurements, with a conservative estimate of required beam time,
are shown in Table III.
TLD Measurements
Both Raju et al. (Ra65) and Dicello (Di76) described using thermoluminescent
dosimeters (TLDs) extensively in pion dosimetry.  Thermoluminescent dosimetry relies on
the “trap” phenomenon in which radiation energy is stored via impurities intentionally
introduced into a crystalline material such as LiF. When heated, the stored energy is released
in the form of visible light, which is then collected via a photomultiplier tube. For these
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are available in 6LiF and 7LiF compositions. Arrays of 6LiF and 7LiF TLD chips will be used
to measure the radiation dose distributions in a phantom similar to that depicted in Figure 4.
6LiF TLD will be employed as an indirect fast neutron dosimeter.  6LiF and 7LiF TLDs both
respond to beta and gamma radiation.  In addition, 6LiF responds to slow neutrons (0.025 eV
to 0.6 MeV) via the 6Li(n,a)3H reaction, for which the cross section is 945 barns.  Two sets
of measurements will be conducted in the phantom described in this proposal.  The first set
will be conducted with the use of 7LiF, and the second set of measurements with 6LiF.  The
6LiF TLD measures slow neutrons that are generated by higher energy neutrons incident on
the phantom and which reflect back into the dosimeter.  Such a dosimeter is referred to as an
albedo dosimeter.  The 7LiF thermal neutron cross section for 7Li(n,a)8Li is only 3.3 barns
and practically measures the gamma dose while the 6LiF gives the dose due to both gamma
rays and neutrons.  The difference in the readings will determine the neutron dose.
BANG and Film Measurements
Three dimensional dose distributions resulting from photon beams have been
successfully measured with the use of Bis Acrylamide Nitrogen Gel (BANG) (Lo99, Ma93,
Ma96a, Ma96b, Ma97).  BANGs are muscle tissue-equivalent in both elemental composition
and density.  These are aqueous gels infused with acrylic monomers that polymerize in
proportion to radiation dose.  During this process, sub-micron sized polymer particles are
created, which are trapped in the gel.  The dose distribution can be obtained by an MRI scan,
using simple pulse sequences easily implemented on any MRI scanner.  Photon-equivalent
dose distribution of an antiproton beam in BANG will be characterized by exposing a
cylindrical flask of BANG to the AD antiproton beam.  Similarly, photon-equivalent dose
distribution of antiproton beams may be measured using a film as a dosimeter, which is a
standard method of obtaining two-dimensional dose distributions.  Because the accuracy and
precision of the film measurements are dependent on measurement conditions and
processing, film dosimetry is not a reliable method of absolute measurements, but it is a
valuable tool for relative measurements and beam alignment.
Bonner Sphere Measurements
To obtain some neutron spectral measurements for comparison with Monte Carlo
calculations, we will use a series of Bonner spheres incorporating 7LiF and 6LiF
thermoluminescent dosimeters and located at a fixed distance from the Bragg peak location in
the other experimental phantoms (Sw98).   This measurement will be concurrent with other
experiments and thus will not require any additional beam time.  The TLD readings will
substitute for the traditional scintillation detector counts (LiI) and their response is dose rate
independent.  The difference in their readings will be assumed to be due to neutrons alone
and this information fed into the unfolding code “Bunkie” to obtain the neutron spectral
information (Jo87).
Cell Irradiation and Post-Analysis
The biological cell sample (cells suspended in solidified agarose growth medium
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placed inside a sterile, thin-film covered tube) will be located immediately adjacent to the
final window of the beamline and aligned collinear to the antiproton beam.  Except for the
front surface of the sample, the sample will be completely surrounded by a phantom, a
rectangular assembly of tissue-equivalent material approximately 30 cm x 30 cm x 30 cm.
The purpose of this phantom is to simulate the human body surrounding a tumor and to
mimic backscattering and energy absorption as they would occur in an actual treatment. To
allow access to the sample, the phantom will be mounted on a rotatable base on top of a
lifting platform allowing for x, y, and z adjustment of the sample with respect to the beam.
The overall footprint of the experiment is approximately 2 m2.  After each irradiation with a
specific dose, the sample tube will be removed from the beamline and transferred to a
biological analysis station.  There the gel will be extruded from the tube in 1 mm slices and
analyzed.  The sample analysis protocol for this step is outlined in Figure 5.  For the purpose
of cell preparation and biological analysis we plan to install a small biolab outside the AD
accelerator hall in an existing container presently owned by the ATHENA collaboration. The
requirements for this laboratory are as follows: electrical power (220 V/3000 Watt);
temperature control to ±  3 ° C; laboratory workbenches; a local self-contained sterile hood for
specimen preparation; an incubator; a CO2 gas bottle; and an optical microscope.  Our
collaboration will cover all expenses for possible upgrades of existing infrastructure to this
container or, if necessary for technical reasons, installation of a new, more suitable container
at this or a similar location.  This small biolab will present no health or safety concerns to
CERN.  It will be in total compliance with all environmental, health, and safety regulations.
The timeline for the assembly and execution of the external biological test beam experiment
is shown in Table II.
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Table II - Proposed timeline for assembly and execution of the external biological test
beam experiment (Note: The work at CERN will utilize nine full AD shifts interspersed
with time periods of off-line sample preparation and data analysis.)
Time Period Work Description Location
20
02 4th Quarter
Design and build sample holder and phantom
Develop cell handling and analysis protocols
Develop biological dosimetry for proton irradiations





Correlate physical and biological dosimetry with protons












Expose living cell suspensions
Incubate and determine biological response
Measure peripheral damage profile
Analyze data and summarize results
CERN
UCLA
We estimate that the total number of shots of antiprotons required to complete the test
beam experiment successfully during the year 2003 can be delivered in nine full shifts,
although some of the measurements can be performed utilizing shorter time periods.  The
timing of the experiment is flexible in that we can make use of gaps in the AD schedule
caused by downtime of the main experiments.  The test beam experiment will essentially
remain in a “standby mode” throughout the run cycle, able to employ antiprotons not used by
the current AD experiments.  We estimate that two shifts will be required to characterize the
beam profile and calibrate the detectors for dosimetry.  The number of antiprotons required to
deliver a total localized dose of 9 Gy in the region of annihilation over a uniform area of 1 cm
x 1 cm is approximately 4x108, or 20 shots at 2x107 antiprotons/shot.  This is the single
highest dose we anticipate needing.  Beam uniformity requirements dictate that only the
central portion of the Gaussian distribution (15 % variation corresponds to 15 % of the beam)
be used for cell irradiations.  This quality beam from the AD would require approximately 7
times more shots (~5 hours) for the single highest dose.  The three highest doses required for
the cell irradiations in this test experiment can be delivered in less than 12 hours.  The
additional smaller doses can be delivered in less than 4 hours.  One additional shift will be
required for the peripheral damage measurements.  The 10 times higher dose needed for
peripheral damage would be able to use all the beam.  Physical characterization of the beam
will require two shifts.  Therefore, the number of shifts to perform the test beam experiment
is 9 (2 for dose characterization, 6 for cell exposures, and 1 for peripheral damage).  The
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estimate for the total beam request is outlined in Table IV.  The 20 % uniform beam
requirement of 2x109 antiprotons is based on preliminary Monte Carlo simulations and
references (Gr84) and (Su85).
Once these measurements are completed, there will be an evaluation phase and a
presentation of the results.  If the results promise significant enhancement over other methods
of delivering localized radiation for therapeutic purposes, we will consider a follow-up
proposal.
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Table III - Time estimates for physical beam characterization based on a conservative
dose rate and anticipated detector response











































<3x1 Gy 0.5 hour 2 1 hour
Current
Calibration
2 hour 1 2 hour
Total 14.5 hours
14












- - 16 2
9 Gy uniform localized dose 2x109 - - -
Additional uniform doses 4x109 - - -
One complete set of samples 6x109 300 16 2
Replicate exposures (x2) 12x109 600 32 4
Peripheral damage ~3x109 ~150 8 1
Total beam time ~72 9
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    Test Beam
          Experiment
0 10 m
Figure 1 - Layout of the biological test beam experiment in the AD accelerator hall.
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Figure 2 - Overview of the biological test beam experiment.  The HPD high-rate
scintillator detectors are not shown to scale.
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Beams Eye View 
Figure 4 - Cross sectional diagram of the TLD array (top view) measuring 6 cm x 6 cm,
with positions of the 1 mm3 microcubes indicated by squares. The assembly will be
placed into a larger phantom for full scatter. The arrow drawn at left indicates the
beam direction. Two-dimensional arrays will stack upon one another as shown from the
beam's-eye-view at the bottom of the figure.
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Sub-culture the cells
     Incubate 6 days
     37 degrees C
     10% CO2
Determine RBE (Relative Biological Effect)
 determine b
     End point vs. dose to calculate RBE
Cell counts iological end points
Colony counts
     Stain the cultured colonies
     Count number of colonies and cells/colony
     Determine survival rate vs exposure
Reference cells (known radiosensitivity)
     V-79 Chinese Hamster
     Maintained in Eagles growth medium
Preparation for Irradiation
     Suspend cells in gel at 7x10cells/cc
     Fill 8 mm x 30 mm sterile sample tubes
5
Irradiations
     Use a phantom to simulate exposure in the body
     Expose to pbars at 7 calculated end-of-range doses
     Expose controls toCo at the same doses for comparison60
Harvesting
     Extrude gel from tube and cut into 2 mm slices
     Dissolve each slice in warm growth medium
     Plate in 100 mm Petri dishes at 100 colonies/plate
     Also measure lateral uniformity
     Replicate plating in triplicate
Figure 5 - Outline of the biological sample analysis protocol.  The experiment will be
performed in triplicate with all doses given within two 8-hour shifts.  There will be a
delay between exposures to allow for sample incubation and analysis.  Two additional 8-
hour shifts will be required to determine the peripheral damage profile.
22
Appendix A
Biographical Sketches of the Members of the Collaboration
Nzhde Agazaryan, Ph.D.
UCLA Medical School
Los Angeles, CA, USA
Education:
·  Ph.D. Biomedical Physics, 2001, UCLA Medical School
·  M.S. Biomedical Physics, 2001, UCLA Medical School
·  B.S. Physics, 1997, University of California, Los Angeles
Appointments:
·  2002 – present, Assistant Clinical Professor, Department of Radiation Oncology, and
Assistant Professor, Interdepartmental Graduate Program in Biomedical Physics, David
Geffen School of Medicine at UCLA
·  2002 – present, Director, Hands-on Course in Intensity Modulated Radiation Therapy,
UCLA Medical Physics Division, Department of Radiation Oncology, University of
California, Los Angeles
·  2000 – present, Adjunct Assistant Professor, Department of Health Sciences, California
State University, Northridge
·  2000 – present, Collaborator in Intensity Modulated Radiotherapy, BrainLAB AG,
ammerthalstrasse 8, 85551 Heimstetten, Germany
·  2000 – present, Chairperson, Electronic Media Committee, American Association of
Physicists in Medicine, Southern California Chapter
Awards/Honors:  Young Investigator Finalist, American Association of Physicists in Medicine
(AAPM), Annual Meeting, 2002, and recipient of the Norman Baily Award, American Association of
Physicists in Medicine, Southern California Chapter, 2001.
Publications: Over 17 peer-reviewed publications and professional presentations.
John J. DeMarco, Ph.D.
UCLA Medical School
Los Angeles, CA, USA
Education:
·  Ph.D. BioMedical Physics, 1997, University of California, Los Angeles
·  M.S. BioMedical Physics, 1995, University of California, Los Angeles
·  B.S. Nuclear Engineering, 1991, The Pennsylvania State University, University Park,
Pennsylvania, USA
Appointments:
·  1999 – present, Assistant Professor (In-residence), Department of Radiation Oncology,
University of California, Los Angeles
·  1998 – 1999, Assistant Clinical Professor, Department of Radiation Oncology, University of
California, Los Angeles






·  Ph.D. Physics, 1988, University of Zurich, Switzerland
·  Diploma, Physics, 1983, ETH Zurich, Switzerland
Appointments:
·  2001 – present, Group Leader, EP-Antiproton experiments, CERN
·  1998, Sabbatical, Stanford University, USA
·  1994 – present, Research Physicist, CERN
·  1993 – 1996, PS/LEAR Coordinator, CERN
·  1991 – 1993, Research Fellowship, CERN
·  1988 – 1991, Research Fellowship, KEK, Japan
·  1988 – present, Group Leader, Meson Spectroscopy, Particle Data Group
Research Interests: Antihydrogen production and spectroscopy, meson spectroscopy.
Publications: More than 100 peer-reviewed publications.
Anthony Joseph Giorgio, M.D.
PBar Medical, Inc.
Newport Beach, CA, USA
Education:
·  M.D. Medicine, 1957, Boston University
·  M.S. Public Health, 1953, Columbia University
·  A.B. Biology, 1952, Boston University
Appointments:
·  2001 – present, Medical Director, PBar Medical, Inc.
·  1988 – 2001, Chairman Oncology Division Department Medicine San Pedro Peninsula
Hospital
·  1996 – 1998, Chairman Department Medicine San Pedro Peninsula Hospital
·  1978 – 2001, Member, Cancer Care Association fulltime hematology/oncology practice
·  1976 – 1978, Professor of Medicine, C.R. Drew School of Medicine
·  1973 – 1978, Associate Professor of Medicine, University of Southern California and C.R.
Drew School of Medicine
·  1973 – 1978, Chief, Hematology/Oncology Division Martin Luther King Hospital, Los
Angeles County/University of Southern California
·  1970-1973, Assistant Professor of Medicine, University of Pittsburgh
Hematology/Oncology Divisions
·  1966 – 1970, Assistant Professor of Pediatrics, New York Medical College
Certifications:
·  Certified by the American Board of International Medicine, 1974
·  Certified by the American Board of Hematology, 1974
Awards/Honors:  Fellow of the American College of Physicians.
Publications:  50 publications including abstracts, short communications, book chapters, and 25 peer-
reviewed publications.
24




·  Ph.D. Physics and Mathematics (Nuclear Physics), 1961, University of Washington
·  B.A. Physics and Mathematics, 1956, University of Montana
Appointments:
·  1992 – 2002, Medical Retirement with low profile contacts with the ATLAS experiment at
CERN
·  1982 – 1992, Collaborator on various experiments at CERN
·  1978 – 1992, Senior Scientist, Detector Instrumentation and Physics, Lawrence Berkeley
National Laboratory
·  1975 – 1978, E10 Group Leader, Los Alamos National Laboratory
·  1970 – 1975, CERN/Max Planck Institut fur Physik und Astrophysik Geneva, Switzerland
and Munchen, Germany, Sabbatical Michigan State University, and Humboldt Stiftung
Sonder Program award
·  1964 – 1974, Professor, Michigan State University (Full Professor, 1968)
Honors/Awards:  Humboldt Stiftung Sonder program, given to selected American full professors of
exceptional talent to work in Europe by the German government.
Publications:  One patent, U.S. Patent 4,243,888, Jan. 6, 1981, Laser Beam Alignment Apparatus and
Method, and numerous publications concerned with detector and detector physics in high-energy and
nuclear physics.
Michael H. Holzscheiter, Ph.D.
PBar Medical, Inc.
Los Alamos, NM, USA
Education:
·  Ph.D. Physics, 1978, University of Mainz, Germany
·  M.S. Physics, 1972, University of Mainz, Germany
Appointments:
·  1986 – present, Staff Member, Los Alamos National Laboratory
·  1998, CERN fellowship
·  1996 – 1999, Spokesperson for CERN experiment AD-1/ATHENA
·  1992 – 1995, Visiting Professor, Pennsylvania State University
·  1990 – 1995, Spokesperson for CERN experiment PS200
·  1983 – 1986, Visiting Assistant Professor, Texas A&M University
·  1981 – 1983, Research Assistant, University of Mainz, Germany
·  1978 – 1981, Postdoctoral Fellow, Texas A&M University
Research Interests:  Experimental physics of trapped ions and electrons, quantum computing with
trapped ions, and low-energy antiproton physics.






·  Ph.D. Multi-Disciplinary Sciences, 2001, Institute of Physics, Graduate School of Arts and
Sciences, University of Tokyo
·  M.S. Multi-Disciplinary Sciences, 1996, Institute of Physics, Graduate School of Arts and
Sciences, University of Tokyo
·  B.S. Faculty of Science, 1994, Kyoto University
Appointments:
·  2001 – present, Assistant Research Professor, University of Aarhus
·  1998 – 1999, Junior Research Associate (JRA) at RIKEN
·  1995 – 1998, Teaching Assistant
Research Interests:  Low-energy collisions of antimatter with matter, especially ionization/excitation
by antiprotons and initial formation processes of antiprotonic atoms and/or molecules.
Publications:  6 publications including conference proceedings.




·  Ph.D. Experimental Atomic Collision Physics, 1977, University of Aarhus
·  M.S. Experimental Atomic Collision Physics, 1973, University of Aarhus
Appointments:
·  1999 – present, Chairman of IFA’s PR committee
·  1998 – present, Member of the Board of the ASACUSA Collaboration at CERN
·  1997 – present, Member of the AD Users Committee (ADUC) at CERN
·  1997 – 2001, Member of the EUROTRAP TMR EEC network
·  1997 – 2001, Member of CRY RING Program Advisory Committee (CPAC) at Stockholm
University
·  1996 – 1999, Member of the ATHENA Collaboration at CERN
·  1995 – 1997, Spokesman for PS194 Collaboration at CERN
·  1990 – 1996, Member of the Board of IFA
·  1987 – 1988, Scientific Consultant, Los Alamos National Laboratory
·  1978 – present, Professor (lector), University of Aarhus
Research Interests: Experimental investigations of charge-changing atomic collisions, with special
emphasis on the behaviour of few electron systems; multiple electron processes and electron
correlation in dynamic systems; impact of particles and their antiparticles on atoms and molecules;
positron physics; production of antihydrogen; photoionization of ions; ultrarelativistic atomic
collisions.
Publications/Conferences:
·  Over 200 scientific articles published, the majority of which are published in peer-reviewed
journals






·  Ph.D. Physics, 1980, University of Mainz, Germany
·  Diploma, Physics, 1978, University of Mainz, Germany
Appointments:
·  2002, Member of Program Advisory Committee, TSL Uppsala, Sweden
·  1999 – present, Spokesperson for CERN experiment AD-1/ATHENA
·  1999 – present, Chairman, CERN Courier Advisory Board
·  1999 – present, Member of Program Advisory Committee, COSY Julich, Germany
·  1997 – 2001, Group leader, EP-Antiproton experiments, CERN
·  1996 – present, AD Physics Coordinator, CERN
·  1995 – 1999, Member of SPSLC Committee at CERN
·  1992 – 1997, Group leader, CERN EP-Crystal Barrel experiment
·  1990 – 1991, PS/LEAR Coordinator, CERN
·  1987 – present, Research Physicist, CERN
·  1985 – 1986, Research Associate, University of Mainz, Germany
·  1983 – 1984, Research Fellowship, CERN
Research Interests: Antihydrogen production and spectroscopy.
Publications/Conferences:
·  More than 100 peer-reviewed publications
·  More than 40 Invited Talks and Colloquia at Conferences and Universities
·  Organizer and Director of 6 international workshops and schools
·  Member of 6 International Advisory Committees
Carl J. Maggiore, Ph.D.
PBar Medical, Inc.
Los Alamos, NM, USA
Education:
·  Ph.D. Nuclear Physics, 1972, Michigan State University
·  B.S. Physics, 1965, Creighton University
Appointments:
·  2000 – present, Chief Scientist, PBar Medical, Inc.
·  1987 – 2000, Head of Ion Beam Materials Lab, Los Alamos National Laboratory
·  1976 – 2000, Staff Member, Center for Materials Science, Los Alamos National Laboratory
·  1974 – 1976, Head of X-Ray Spectrometer Division, Princeton Gamma Tech, Inc.
·  1970 – 1974, Research Associate, Mount Sinai Medical School
Research Interests: Ion-solid interactions, radiation damage, characterization, analysis, and
modification of materials using ion beam methods, channeling of ions in solids, surface damage in
materials.
Honors/Awards: Recipient of a Distinguished Performance Award, Los Alamos National
Laboratory, 1992, and Member of the New York Academy of Sciences and the Bohmische Physical
Society.
27
Publications: More than 100 peer-reviewed publications in the fields of nuclear physics, health,
radiation damage, ion beam analysis, and materials science.
William H. McBride, D.Sc.
UCLA Medical School
Los Angeles, CA, USA
Education:
·  FRC Path, Pathology, 1990, Royal College of Pathologists, England
·  D.Sc. Medical Sciences, 1987, University of Edinburgh, Scotland
·  Ph.D. Medical Sciences, 1971, University of Edinburgh, Scotland
·  B.Sc. Honors, Zoology, 1966, University of Edinburgh, Scotland
Appointments:
·  1995 – present, Vice-Chair (Research), Department of Radiation Oncology, University of
California, Los Angeles
·  1994 – present, Director, Division of Experimental Radiation Oncology, Department of
Radiation Oncology, University of California, Los Angeles
·  1984 – present, Professor, Department of Radiation Oncology, University of California, Los
Angeles
·  1982 – 1984, Sr. Lecturer, Department of Bacteriology, University of Edinburgh Medical
School
·  1972 – 1982, Lecturer, Department of Bacteriology, University of Edinburgh Medical
School, Edinburgh, Scotland
Research Interests: Radiobiology; involvement of growth factors and signal transduction pathways
in the radiation response of normal tissues and tumors.
Publications: Over 220 peer-reviewed publications.




·  D.Sc. Physics, 1998, University of Aarhus
·  Ph.D. Physics, 1986, University of Aarhus
·  M.S. Physics and Mathematics, 1981, University of Aarhus
Appointments:
·  1999 – present, Director of ISA
·  1997 – present, Consultant for DANFYSIK A/S in accelerator physics
·  1996 – 1999, Technical Director of ISA, Institute for Storage Ring Facilities
·  1988 – 1996, Head of Laboratory at the ASTRID storage ring
·  1983 – 1988, Research Associate in CERN physics at Institute of Physics, University of
Aarhus
·  1981 – 1983, Fellow at CERN
Honors/Awards: Recipient of the European Particle Accelerator Prize, European Physical Society,
1998.
Research Interests: Interaction of high-energy particles with matter (channeling, gamma-radiation,
28
etc.), antiproton interactions with matter (LEAR, AD), and accelerator physics, related to ion-
accelerators and storage rings, and electron storage rings for synchrotron radiation production.
Publications: Author/co-author on over 80 international publications in scientific journals and
proceedings.
James B. Smathers, Ph.D.
UCLA Medical School
Los Angeles, CA, USA
Education:
·  Ph.D. Nuclear Engineering, 1967, University of Maryland
·  M.S. Nuclear Engineering, 1959, North Carolina State College
·  B.N.E. Nuclear Engineering, 1957, North Carolina State College
Appointments:
·  2001 – present, Professor Emeritus, Department of Radiation Oncology, University of
California, Los Angeles
·  1980 – 2001, Professor and Director of Medical Physics, Department of Radiation
Oncology, University of California, Los Angeles
·  1976 – 1980, Professor and Head of Bioengineering, Texas A&M University
·  1973 – 1980, Professor of Nuclear Engineering, Texas A&M University
·  1971 – 1973, Associate Professor, Nuclear Engineering, Texas A&M University
·  1967 – 1971, Assistant Professor, Nuclear Engineering, Texas A&M University
·  1961 – 1967, Section Chief, Walter Reed Army Institute of Research
Honor/Awards: Principal U.S. Representative, I.A.E.A Advisory Group on Advances in Dosimetry
for Fast Neutrons and Heavy Charged Particles, 1982.
Publications: Over 100 peer-reviewed publications.
Timothy D. Solberg, Ph.D.
UCLA Medical School
Los Angeles, CA, USA
Education:
·  Ph.D. Medical Physics, 1996, University of California, Los Angeles
·  M.S. Physics, 1988, University of California, Davis
·  B.S. Physics, Mathematics, 1985, Augsburg College
Appointments:
·  2001 – present, Director of Medical Physics, Department of Radiation Oncology, University
of California, Los Angeles
·  2000 – present, Associate Professor, Department of Radiation Oncology, University of
California, Los Angeles
·  1996 – 2000, Assistant Professor, Department of Radiation Oncology, University of
California, Los Angeles
·  1996 – present, Associate Professor, Biomedical Physics Graduate Program, University of
California, Los Angeles
·  1996 – present, Co-Director, Radiosurgery Program, Department of Radiation Oncology
and Division of Neurosurgery, University of California, Los Angeles
29
Honors/Awards: Recipient of a Research Scholar Grant, American Cancer Society, 2002, and The
Whitaker Foundation Research Award, 1999.
Publications: 87 peer-reviewed publications.




·  Ph.D. High-Energy Physics, 1997, University of Aarhus/CERN
·  M.Sc. Atomic Physics, 1994, University of Aarhus
Appointments:
·  2000 – present, closely involved in various test beam experiments at the CERN Super
Proton Synchrotron (SPS)
·  1999 – present, Associate Professor, Department of Physics and Astronomy, University of
Aarhus
·  1997 – 1999, Postdoc, worked on the construction of the CERN Antiproton Decelerator
(AD), designed the optics for the AD beam lines and extraction from the AD in
collaboration with Massimo Giovanozzi and Pavel Belochitski
·  1992 – present, Researcher, CERN, various experiments starting with antiprotons at the
Low Energy Antiproton Ring (LEAR)
·  1992 – present, member of several collaborations including PS194, NA43, P305, NA59,
ATHENA, ASACUSA and LPM
Publications: 63 publications in peer-reviewed journals.
H. Rodney Withers, M.D., Ph.D., D.Sc.
UCLA Medical School
Los Angeles, CA, USA
Appointments:
·  Professor and Chair, Department of Radiation Oncology, UCLA Medical School
·  Clinical Research Professor of the American Cancer Society
Honors/Awards: Recipient of the Henry S. Kaplan Distinguished Scientist Award from the
International Association for Radiation Research, the Gold Medal from the American Society for
Therapeutic Radiology and Oncology, the Polish Academy of Science Medicine Prize, and the Gray
Medal (1995).
Research Interests: Post radiation repair and the effects of ionizing radiation on normal tissues.
